Invention Grant
- Patent Title: Therapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs
-
Application No.: US16964236Application Date: 2019-01-25
-
Publication No.: US11773169B2Publication Date: 2023-10-03
- Inventor: Mitsuro Kanda
- Applicant: YMMUNOBIO AG
- Applicant Address: CH Riehen
- Assignee: YMMUNOBIO AG
- Current Assignee: YMMUNOBIO AG
- Current Assignee Address: CH Riehen
- Agency: FOX ROTHSCHILD LLP
- Priority: JP 18011937 2018.01.26
- International Application: PCT/JP2019/002504 2019.01.25
- International Announcement: WO2019/146759A 2019.08.01
- Date entered country: 2020-07-23
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/04 ; C12N15/113 ; G01N33/574 ; A61K39/00
Abstract:
From gene expression analysis with a long-term recurrence-free group and a recurrence metastasis group of stomach cancer, CHRNB2 and NPTXR were identified as drug discovery targets. Tumor growth was successfully inhibited by an antibody medicine or a nucleic acid medicine targeting CHRNB2 or NPTXR. Furthermore, a polyclonal antibody and a monoclonal antibody linking to CHRNB2 or NPTXR are provided. Since these receptor molecules are novel molecular targets, treatment of cases which the existing therapeutic drugs have no effect on is made possible.
Public/Granted literature
Information query
